136 related articles for article (PubMed ID: 35181864)
21. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
[TBL] [Abstract][Full Text] [Related]
22. Casirivimab/Imdevimab: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
[TBL] [Abstract][Full Text] [Related]
23. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato Y; Yamamoto K; Nakaya Y; Morioka S; Takeuchi JS; Takamatsu Y; Maeda K; Kimura M; Sugiura W; Mitsuya H; Yano M; Ohmagari N
J Infect Chemother; 2022 Jul; 28(7):991-994. PubMed ID: 35337728
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
[TBL] [Abstract][Full Text] [Related]
25. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Antibody Therapeutics for COVID-19.
Hurt AC; Wheatley AK
Viruses; 2021 Apr; 13(4):. PubMed ID: 33916927
[TBL] [Abstract][Full Text] [Related]
27. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR; Ku Z; An Z; Carroll SF; Keyt BA; Strohl LM
BioDrugs; 2022 May; 36(3):231-323. PubMed ID: 35476216
[TBL] [Abstract][Full Text] [Related]
28. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
29. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
30. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
Hooper AT; Somersan-Karakaya S; McCarthy SE; Mylonakis E; Ali S; Mei J; Bhore R; Mahmood A; Geba GP; Dakin P; Weinreich DM; Yancopoulos GD; Herman GA; Hamilton JD;
mBio; 2022 Dec; 13(6):e0169922. PubMed ID: 36255239
[TBL] [Abstract][Full Text] [Related]
31. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
Lin YJ; Evans DH; Robbins NF; Orjuela G; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2022 Oct; 10(5):e0281122. PubMed ID: 36125288
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
33. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
34. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
[TBL] [Abstract][Full Text] [Related]
35. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
36. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
[TBL] [Abstract][Full Text] [Related]
38. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
39. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA
PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792
[TBL] [Abstract][Full Text] [Related]
40. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD
J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
